Drug profile · INN
filgotinib
JYSELECA
filgotinib (JYSELECA) is a tyrosine-protein kinase jak3 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AF04
Patents linked 1
Pipeline programs 24
News articles 0
Drug details — filgotinib
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 1
- Programs
- 24
- Data quality
- 0.83
Quick answer
filgotinib (JYSELECA) is a tyrosine-protein kinase jak3 inhibitor.
Reviewed by Sarah Chen Editor-in-Chief Last reviewed Jun 8, 2026
Key facts
INN filgotinib
Brand JYSELECA
Mechanism Tyrosine-protein kinase JAK3 inhibitor
Target Tyrosine-protein kinase JAK1
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AF04
Mechanism of action
Tyrosine-protein kinase JAK3 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
Regional status spokes: EMA status
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is filgotinib?
filgotinib (JYSELECA) is a tyrosine-protein kinase jak3 inhibitor.
What is the brand name for filgotinib?
JYSELECA is a marketed brand name for filgotinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.